Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a report published on Monday morning.

A number of other analysts have also commented on MRNS. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Truist Financial reissued a buy rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $10.25.

Marinus Pharmaceuticals Stock Down 0.7 %

Marinus Pharmaceuticals stock opened at $1.39 on Monday. The stock has a market capitalization of $76.56 million, a PE ratio of -0.53 and a beta of 1.13. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The company has a 50 day moving average of $1.34 and a 200-day moving average of $3.22.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter last year, the company earned ($0.61) EPS. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Hussman Strategic Advisors Inc. raised its stake in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares during the period. AQR Capital Management LLC lifted its holdings in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the second quarter worth $28,000. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the second quarter valued at $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Marinus Pharmaceuticals in the first quarter valued at about $384,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.